Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

FDA to speed up gene therapy and regenerative medicine approvals

20 November 2017

By Martha Henriques

Appeared in BioNews 927

The US Food and Drug Administration (FDA) has announced a fast-track review process for gene therapies and other regenerative medicine treatments.

The new draft guidelines are an attempt to bring effective gene therapies to market more quickly. So far, the FDA has only approved two such treatments, which treat leukaemia and lymphoma. The updated guidelines will also speed up approval of stem cell based treatments that could treat serious or otherwise untreatable illnesses.

'These concepts are no longer the stuff of science fiction,' said Dr Scott Gottlieb, commissioner of the FDA. 'We’re at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body… where new genes can be introduced into the body to combat disease; and where adult stem cells can generate replacements for cells that are lost to injury or illness.'

In addition to the fast-track process, the FDA has clarified several points to help researchers and drug developers understand whether their treatments are considered higher risk, requiring pre-market regulation, or whether they fall into a lower-risk category.

Researchers and therapy developers have welcomed the new guidelines.

'This is an incredibly significant development for the gene therapy, regenerative medicine sector,' Michael Werner, a lawyer and co-founder of the Alliance for Regenerative Medicine, told the New York Times. 'This should really open the door to a lot more gene therapies coming on the market quickly.'

However, Dr Michael Carome, director of non-profit organisation Public Citizen's health research group, told the newspaper that there was 'excessive hype' around the guidelines. 'We are talking about rushing to market very complex biologics products where we are still in the infancy of this field,' he said.

Clinical trials will remain an essential element of the accelerated approvals process, the FDA said. At the same time, the agency plans to crack down on illegitimate clinics offering unproven and often risky procedures. 

This is overdue, said Dr Leigh Turner, an associate professor at the University of Minnesota's Centre for Bioethics in Minneapolis, Minnesota. The market for unproven treatments with no basis in evidence is 'quite large, quite active and [it's been there] a long time without meaningful oversight', he told Regulatory Focus. Many of these clinics purport to use stem cells derived from fat tissue. These procedures will now be brought under the FDA's remit.

Dr Peter Marks, director of the FDA's centre for biologics evaluation and research, said at a news conference: 'Our goal here is not to flood the market with products. It's to get products on that are safe and effective, and to clear up the field so that people know what they have to do.'

SOURCES & REFERENCES
US Food & Drug Administration | 16 November 2017
 
The New York Times | 16 November 2017
 
Regulatory Affairs Professionals Society Focus | 16 November 2017
 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

27 November 2017 - by Theofanis Michailidis 
The US Food and Drug Administration (FDA) is taking an active stance against the use of 'do it yourself' gene therapy kits...

13 November 2017 - by Jamie Rickman 
The US Food and Drugs Administration has further deregulated direct-to-consumer genetic health risk tests, meaning that some will be approved for market without a pre-market review...
19 October 2017 - by Jennifer Willows 
The US Food and Drug Administration have approved the world’s second gene therapy to target blood cancer...
16 October 2017 - by Rikita Patel 
The US Food Drug and Administration advisory committee has backed the use of gene therapy to treat a hereditary disease for the first time...
09 October 2017 - by Jennifer Willows 
The reputation of stem cell research is being undermined by unscrupulous clinics offering unproven therapies, says a report published last week...
04 September 2017 - by Rikita Patel 
The US Food and Drug Administration intends to investigate the use of unproven stem cell therapies being offered in the country's clinics...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation